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Abstract Von Hipple–Lindau gene (VHL) inactivation
represents the most frequent abnormality in clear cell renal
cell carcinoma (ccRCC). Hypoxia-inducible factor-1a
(HIF-1a) expression is regulated by O2 level. In normal O2
conditions, VHL binds HIF-1a and allows HIF-1a prote-
asomal degradation. A single-nucleotide polymorphism
(SNP) has been found located in the oxygen-dependent
degradation domain at codon 582 (C1772T, rs11549465,
Pro582Ser). In hypoxia, VHL/HIF-1a interaction is abol-
ished and HIF-1a activates target genes in the nucleus. This
study analyzes the impact of genetic alterations and protein
expression of VHL and the C1772T SNP of HIF-1a gene
(HIF-1a) on prognosis in early-stage ccRCC (pT1a, pT1b,
and pT2). Mutational analysis of the entire VHL sequence
and the genotyping of HIF-1a C1772T SNP were per-
formed together with VHL promoter methylation analysis
and loss of heterozygosis (LOH) analysis at (3p25) locus.
Data obtained were correlated with VHL and HIF-1a
protein expression and with tumor-specific survival (TSS).
VHL mutations, methylation status, and LOH were detec-
ted in 51, 11, and 12 % of cases, respectively. Our results
support the association between biallelic alterations and/or
VHL silencing with a worse TSS. Moreover, we found a
significant association between the HIF-1a C1772C geno-
type and a worse TSS. The same association was found
when testing the presence of HIF-1a protein in the nucleus.
Our results highlight the role of VHL/HIF-1a pathway in
RCC and support the molecular heterogeneity of early-
stage ccRCC. More important, we show the involvement of
HIF-1a C1772T SNP in ccRCC progression.
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Introduction
Renal cell carcinoma (RCC) is the most common malig-
nant tumor in the adult kidney, accounting for about 3 % of
all human malignancies with the clear cell subtype
(ccRCCs) represented 80 % of all RCCs [1].
One of the most common alterations in sporadic ccRCC
is the biallelic inactivation of Von Hipple–Lindau gene
(VHL) due to mutation, promoter hypermethylation, or loss
of heterozygosity (LOH) of chromosome 3p [2, 3].
Von Hipple–Lindau gene is a tumor suppressor gene
(TSG) mapping at 3p25–26 and containing three exons [1].
Under normal conditions, the protein encoded by VHL,
pVHL, localizes preferentially in the cytoplasm maintain-
ing, however, the ability to shuttle between cytoplasm and
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nucleus [4]. pVHL exists in two different isoforms:
pVHL30 and pVHL19 [4]. pVHL19 has been shown to
contribute to the formation of an ubiquitin ligase (E3)
complex (VEC), which controls the proteasomal degrada-
tion of several target genes including the hypoxia-inducible
factor-1a (HIF-1a) [5]. The ability of pVHL and HIF-1a to
bind each other depends upon the cellular oxygen level.
Under normal oxygen conditions, HIF-1a is hydroxylated
in the nucleus on conserved prolyl residues (Pro 402 and
Pro 564) within the oxygen-dependent degradation (ODD)
domain [6]. Hydroxylated HIF-1a is able to bind pVHL
and such binding allows its polyubiquitination and its
consequent degradation [6]. On the contrary, under hypoxic
conditions, the non-hydroxylated HIF-1a cannot bind
pVHL and is free to translocate into the nucleus. Once in
the nucleus, HIF-1a dimerizes with the HIF-1b subunit and
trans-activate its target genes [6], which are mainly
involved in the resistance to hypoxia, in the glucose uptake
and metabolism (Glut1), regulation of extracellular pH
(CAIX), angiogenesis (VEGF), erythropoiesis (EPO), and
mitogenesis (PDGF-B) [5].
Von Hipple–Lindau gene alterations suppress the ability
of pVHL proteins to bind HIF-1a causing the constitutive
expression of HIF-1 and its inducible genes [7]. Of note, HIF-
1a expression has been shown to be high in ccRCC [7].
Von Hipple–Lindau gene inactivation can occur through
mutation (approximately 50 %) [2, 7, 8], hypermethylation
(10–20 %) [2, 9], and/or LOH (84–98 %) at locus 3p25 [10].
In our previous study, we showed that the cytoplasmic-
nuclear trafficking of pVHL is blocked in ccRCC and the
absence of pVHL concurrently associates with a strong
HIF-1a expression [11]. A relatively recent study from
Kim et al. [12] showed that a SNP mapping in the HIF-1a
ODD domain (C1772T, rs11549465) associates with HIF-
1a protein expression in breast cancer. This SNP leads to a
proline to serine substitution at codon 582 [13, 14].
Although C1772T has been shown not to affect the
hydroxylation process [15], it might confer susceptibility to
RCC and its presence has been demonstrated to correlate
with the development of metastases [14]. Here, we evalu-
ated the prognostic significance of such SNP in ccRCC
patients. It should be noted that although a growing number
of evidence on the molecular alterations underlying ccRCC
pathogenesis is currently being accumulated [16], the
prognostic relevance of such alterations still lacks of an
appropriate investigation. Moreover, contrarily to the
majority of the studies already published in the literature,
which pool together samples from RCC patients at differ-
ent stages, we specifically selected a cohort of 136 early-
stage ccRCC patients (pT1a, pT1b, and pT2). By simul-
taneously analyzing clinical samples through direct
sequencing, DNA promoter methylation, immunohisto-
chemistry and survival analyses, we show here the ccRCC
molecular heterogeneity and evaluate the prognostic sig-
nificance of VHL and HIF-1a molecular alterations in this
specific subset of early-stage ccRCC patients.
Materials and methods
Tumor samples
Formalin-fixed paraffin embedded (FFPE) tissues were
collected from a total of 136 intracapsular early-stage
ccRCC patients (pT1a, pT1b, and pT2) (mean age 62 year,
range 28–85), who underwent radical nephrectomy from
1991 to 2001. Clinical characteristics of this series are
reported elsewhere [17]. The evaluation of pathological
staging, histotype, nuclear grading, and DNA content was
performed as previously described [17].
Tissue microarrays
Tissue microarrays (TMAs) were established in order to avoid
inter-analysis variability during IHC. Core tissue biopsies
(1 mm in diameter) were taken from morphologically repre-
sentative, non-necrotic regions of individual RCC tumor sam-
ples and arrayed into new paraffin blocks (45 9 20 mm2)
using Chemicon ATA-100 Tissue Arrayer (Chemicon Inter-
national Inc., Temecula, CA, USA). Sections of the TMA
blocks (5-mm thick) were transferred to glass slides. Each
TMA contained 50 tissue cylinders: ten from each of the three
primary tumor areas and ten from each of the two paired normal
tissues. TMA sections were then deparaffinized and rehydrated.
Immunohistochemistry
Two commercially available monoclonal pVHL antibodies,
clone Ig32 (BD-Bioscience, San Jose, CA, USA) and clone
Ig33 (Lab Vision, Kalamazoo, MI, USA), were used at
1:50 and 1:200 dilution, respectively, with clone 32 rec-
ognizing both pVHL30 and pVHL19 isoforms and clone 33
specific for pVHL30. A polyclonal anti-HIF-1a antibody
(Zymed, Las Condes, Santiago, Chile) was used at 1:50
dilution. The reactions were performed in an automated
system (BenchMark XT Ventana, Oro Valley, AZ, USA)
and the avidin–biotin peroxidase method was used for
visualization. Each IHC analysis was done in duplicate.
VHL sequencing analysis
Von Hipple–Lindau gene sequence was screened for
mutations by direct sequencing. Genomic DNA was iso-
lated from FFPE samples, using QIAmp DNA Mini Kit
(Qiagen, Germantown, MD, USA), following the manu-
facturer’s instructions. Primers were designed using
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Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) (Table 1).
PCR was performed using 9700 GeneAmp PCR System
(Applied Biosystems, Foster City, CA, USA) following stan-
dard procedure: initial denaturation at 95 C for 7 min; 40
cycles at 94 for 45 s, specific annealing temperature for 45 s,
72 C for 1 min; final step at 72 C for 10 min. PCR products
were purified and labeled using Big Dye terminator kit version
3.1 (Applied Biosystems, Foster City, CA, USA). Sequencing
was then performed using Biosystems 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) and analyzed by
sequencing analysis software 3.4 version.
In order to avoid artifacts arising from technical issues,
we repeated all the molecular analyses (included the ones
described below) 3 times for each samples.
LOH analysis at locus 3p
Loss of heterozygosis was assessed for the D3S1597 and
D3S1038 microsatellites located at 3pter–3p24.2 and
3p26.1–3p25.2, respectively.
Primers are reported in Table 1. PCR was performed as
described above. PCR products (163 bp length for D3S1597
and 174 bp length for D3S1038) were loaded on ABIPRISM
3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA) and analyzed by GeneScan software.
VHL promoter methylation-specific PCR
One lg of genomic DNA was bisulfite-converted using EZ
DNA Methylation Kit (Zymo Research Irvine, CA, USA).
A positive control was created using human blood treated
with CpG Methylase (SssI) (Roche, Basel, Switzerland).
PCR amplification was then performed using primers
specific for methylated and unmethylated DNA as descri-
bed by Kuroki et al. [18]. PCR was carried out as described
above. PCR products were finally run on a 3 % agarose gel
with appropriate size markers.
HIF-1a C1772T SNP sequencing
A 178-bp-length PCR region including C1772T SNP was
amplified as described above using the primers reported in
Table 1. The PCR product was then purified, labeled, and
sequenced as described above.
Table 1 Primer sequences
VHL1a forward 50-GGTCTGGATCGCGGAGGGA-30
VHL1a reverse 50-GCCCGGCCTCCATCTCCT-30
VHL1b forward 50-GCGGAGAACTGGGACGAG-30
VHL1b reverse 50-GCGATTGCAGAAGATGACCT-30
VHL1c forward 50-GCCGAGGAGGAGATGGAG-30
VHL1c reverse 50-GCTTCAGACCGTGCTATCGT-30
VHL2 forward 50-AACCTTTGCTTGTCCCGATA-30
VHL2 reverse 50-CAGGCAAAAATTGAGAACTGG-30
VHL3 forward 50-GATTTGGTTTTTGCCCTTCC-30
VHL3 reverse 50-CCATCAAAAGCTGAGATGAAA-30
C1772T forward 50-GCTCCCTATATCCCAATGGA-30
C1772T reverse 50-CAGTGGTGGCAGTGGTAGTG-30
D3S1597 forward 50-CACACAAATGTCTCTCCCTGTG-30
(FAM)
D3S1597 reverse 50-TCGTTCATTGCTCAAACTCTTT-30
D3S1038 forward 50-CACGGGAGTCTACAGCTTGG-30 (FAM)
D3S1038 reverse 50-TCTGCTCAACTCCCTCCAGT-30
Table 2 List of VHL mutations detected in this study
Sample Mutation Description Hetero/homo
1 c. 224_225del Deletion Heterozygous
2 c. 484T[C Transition Heterozygous
3 c. 220_240dup20 Duplication Heterozygous
4 c. 294del Deletion Heterozygous
5 c. 452T[C Transition Heterozygous
6 c. 416del Deletion Heterozygous
7 c. 497T[A Transversion Heterozygous
8 c. 509del Deletion Heterozygous
9 c. 164del Deletion Heterozygous
10 c. 266 T[A Transversion Heterozygous
11 c. 160_174del Deletion Heterozygous
12 c. 494T[A Transversion Heterozygous
13 c. 242 C[T Transition Homozygous
14 c. 259G[A Transition Homozygous
14 c. 343C[T Transition Homozygous
14 c. 559G[A Transition Homozygous
15 c. 434del Deletion Heterozygous
16 c. 388G[A Transition Homozygous
16 c. 463G[A Transition Homozygous
17 c. 221T[A Transversion Homozygous
18 c. 461C[T Transition Homozygous
18 c. 625C[T Transition Heterozygous
19 c. 424G[A Transition Homozygous
20 c. 213_233dup20 Duplication Heterozygous
21 c. 263_270del Deletion Heterozygous
22 c. 287del Deletion Heterozygous
23 c. 263G[A Transition Homozygous
24 c. 238A[T Transversion Heterozygous
24 c. 239G[T Transversion Heterozygous
25 c. 309del Deletion Heterozygous
26 c. 217_225dup8 Duplication Heterozygous
27 c. 343C[A Transversion Heterozygous
28 c. 368G[A Transition Homozygous
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Statistical analysis
Two-tailed chi-square test was used to assess differences in
pVHL and HIF-1a molecular status and protein expression.
Survival probability was estimated by Kaplan–Meier method.
All the statistical analyses were performed using MedCalc
(MedCalc Software, Ostend, Belgium) and Instat3 software
(GraphPad Software, Inc. La Jolla, CA, USA).
Results
VHL mutational analysis
Von Hipple–Lindau gene mutational analysis was per-
formed in 55 cases out of the 136 samples available. VHL
mutations were detected in 28/55 (51 %) ccRCCs. Four
additional patients presented multiple mutations. The
mutations were located in exon 1 (17/33, 51 %), in exon 2
(10/33, 30 %), and in exon 3 (6/33, 18 %). Among the
13/33 (39 %) truncating mutations, 11 were frameshift and
2 were non-sense mutations. All known mutations detected
in this study (Table 2) have been reported previously in the
Human Gene Mutation Database (Institute of Medical
Genetics in Cardiff: The Human Gene Mutation Database;
www.hgmd.cf.ac.uk/ac/) and in the Catalogue of Somatic
Mutations in Cancer (COSMIC; www.sanger.ac.uk/genet
ics/CGP/cosmic/).
LOH analysis at VHL locus 3p
Loss of heterozygosis was assessed in 79 and 75 cases at
the marker loci D3S1038 (centromeric to VHL locus) and
D3S1597 (telomeric to VHL locus), respectively. Sixty-one
cases were informative for D3S1038 and 64 cases were
informative for D3S1597. LOH was found in 15/79 (19 %)
and 21/75 (28 %) for D3S1038 and D3S1597, respectively.
Forty-one cases have been analyzed for both microsatel-
lites. 6/49 (12 %) cases presented LOH in both the markers
and 12/49 (24 %) and 19/49 (39 %) cases had D3S1038
and D3S1597 LOH, respectively.
VHL promoter methylation-specific PCR
Von Hipple–Lindau gene promoter methylation was ana-
lyzed in 53 cases. VHL promoter was found methylated in
6/53 (11 %) cases. No case presented promoter methyla-
tion in both alleles.
HIF-1a C1772T SNP
HIF-1a C1772T SNP was genotyped in 117 cases. The
1772T allele was present in 35/117 (30 %) cases. The
variant allele (T) was present in heterozygosis (C/T) in
30/35 (86 %) and in homozygosis (T/T) in 5/35 (14 %).
In order to investigate whether the genotype and allele
frequencies of this SNP in our cohort of ccRCC patients
differed from the ones reported for healthy individuals in
the 1000 Genome Project, we selected the European pop-
ulations from the 1000 Genome Project dataset (EUR) and
compared the genotype and allele frequencies. Concordant
to the literature [19], we found a higher T allele and TT
genotype frequency in our cohort of ccRCC patients
compared with the European healthy subjects from the
1000 Genome Project (Fig. 1), supporting the cancer-pre-
disposing role of the T allele. Although we acknowledge
that a control group should have been recruited from the
same population of the ccRCC patients, we believe that the
comparison with the 1000 Genome project data provides
indication of the potential role of the C1772T SNP in
predisposing for ccRCC.
VHL gene variation and protein expression
No significant association was found between VHL muta-
tion, microsatellite, or methylation analysis (taken as sin-
gular molecular events) and VHL or HIF-1a protein
expression. Thus, we decided to pool together samples with
two alterations (biallelic).
Out of 50 cases analyzed for VHL mutation, LOH and
methylation:
• 16/50 (32 %) cases presented biallelic alterations meant
as mutation in homozygosis or as presence at the same
Fig. 1 Pie charts of the allele and genotype frequencies of HIF-1a
C1772T SNP in the EUR populations of the 1000 Genome Project and
our cohorts of early ccRCC, respectively
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time of LOH and mutation, LOH and methylation or
methylation and mutation;
• 15/50 (30 %) cases had only one alteration (mutation,
LOH and methylation);
• 19/50 (38 %) cases carried no alteration.
The association between pVHL expression and the bi-
allelic alteration of VHL was assessed in a total of 46
samples for which all the molecular data were available
without reaching statistical significance (Table 3).
HIF-1a C1772C genotype associates with HIF-1a
protein expression
When assessing the association between the HIF-1a
C1772C genotype and HIF-1a protein expression, we
found that the HIF-1a C1772C homozygous genotype
(absence of the pathological variant) significantly associ-
ates with a higher HIF-1a protein nuclear expression
(p = 0.021) (Table 4).
VHL biallelic variations and tumor-specific survival
(TSS)
We then grouped together the normal samples and those
with the monoallelic alteration; we found that overall
samples carrying biallelic alterations had a worse TSS as
compared to samples with no molecular alterations. How-
ever, such association did not reach statistical significance
(Fig. 2a).
HIF-1a C1772T SNP and TSS
We further analyzed the correlation between TSS and
HIF1a C1772T SNP. Overall, samples carrying the T/T
genotype tended to have a better prognosis as compared to
samples carrying the C/C and C/T genotype (Fig. 2b).
Discussion
Renal cell carcinoma has been described as made up of
several cancers, having different histology and character-
ized by a different clinical course and response to therapy
[20]. The ccRCC subtype accounts for 80 % of sporadic
RCCs and can often be cured, if diagnosed on time, and
treated when still localized to the kidney (intracapsular)
[1]. Overall, intracapsular ccRCCs are known to have a
good prognosis. However, 15–20 % of patients might
develop recurrence and eventually die for the disease [21].
The inactivation of the VHL tumor suppressor protein
and the deregulation of VHL/HIF-1a axis are common
events in ccRCC [5]. The role of pVHL has been exten-
sively studied [5]. pVHL is a multifunctional protein whose
function has been clearly linked to kidney carcinogenesis
due to its role in the polyubiquitination process. The
expression of pVHL is often found altered in ccRCC due to
mutations, promoter methylation and LOH of the VHL.
When assessing the VHL mutational status in our cohort,
we found that VHL coding sequence was mutated in 51 %
of cases, with exon 1 being the most mutated, as already
shown in a previous study [8]. A wide discrepancy exists in
literature about the VHL mutation frequency in ccRCC,
ranging between 21 and 66 % [22, 23], which may be
explained by the different ethnic origin of the populations
recruited in the different studies or, more importantly, by
the differential efficiency of the technical approaches
applied (for example Sanger sequencing is more sensitive
than SSCP).
The frequency of VHL LOH at 3p25–26 detected in our
study was 11 %, which resulted lower than the one
reported in the literature [24, 25]. This could be explained
by the fact that we analyzed exclusively early-stage intra-
capsular ccRCCs while other studies grouped together
RCC samples at different stages of progression. Thus, it is
likely that LOH may be a molecular event, which gradually
accumulates during tumor progression.
Von Hipple–Lindau gene promoter was found methyl-
ated in 11 % of cases, concordantly to the findings of other
studies, which have reported VHL promoter hypermethy-
lation in 7–11 %, cases examined [2, 9].
The prognostic relevance of VHL molecular alterations
in patients with sporadic ccRCCs remains to be established.
Few studies have addressed the issue of clinical impacts of
somatic VHL alterations in sporadic RCCs reporting,
however, conflicting results [2, 15, 26]. Brauch et al. [2]
have showed a significant association between VHL alter-
ations (mutation and methylation) and advanced RCC
Table 3 Correlation between biallelic VHL alterations and pVHL
expression
pVHL? pVHL- Total
Non-biallelic alterations 28 3 31
Biallelic alterations 13 2 15
Total 41 5 46
v2 = 0.14, p = 0.7
Table 4 Correlation between HIF-1a C1772T SNP and the presence
of HIF-1a in the nucleus
C/T ? T/T C/C Total
HIF-1a nucleus? 11 50 61
HIF-1a nucleus- 15 23 38
Total 26 73 99
p = 0.021
Med Oncol (2014) 31:840 Page 5 of 7 840
123
tumor stage. Similarly, Schraml et al. [27] showed that
ccRCC with VHL open reading frame mutations, which
potentially lead to pVHL loss of function, are associated
with a worse prognosis. Kondo et al. [26], in another study,
were not able to find any significant association between
VHL alteration and disease prognosis.
When assessing here the clinical impact of VHL
molecular alterations on the prognosis, we found that
overall patients with biallelic VHL alterations had a shorter
TSS, supporting the relevance of VHL in RCC carcino-
genesis. However, this association did not reach statistical
significance, maybe because the casuistic recruited was not
large enough to allow the detection of statistical signifi-
cance. Larger sample size studies are warranted to exploit
this issue.
No association between VHL mutation, methylation and
LOH analysis taken as a singular molecular event and TSS
was found in this study, supporting the VHL function as
TSG. Indeed, TSGs generally require multiple inactivation
events to loose their function, according to the two-hits
Knudson hypothesis.
Another important player in RCC development is HIF-
1a. HIF-1a resides on chromosome 14q, whose homozy-
gous deletion leads to absent protein production [28]. In
some cases, alternative mRNA splicing around deleted
HIF-1a exonic sequence leads to the production of aberrant
HIF-1a isoforms [28]. Although rare, intragenic HIF-1a
mutations, including missense mutations, have been
described in clear renal carcinoma tumors [28]. Besides
mutational events, inherited polymorphisms might also
play a role in RCC carcinogenesis. A common SNP map-
ping in the ODD domain in exon 12 of HIF-1a (C1772T,
Pro582Ser) has been described in the literature [13, 29].
Although not involved in the process of hydroxylation [14],
this SNP may confer susceptibility to renal cancerogenesis
and progression. Supporting this hypothesis, Kim et al. [8]
showed that the Pro582Ser change contributes to the
development of metastases. When comparing the distri-
bution of this SNP in our cohort with the 1000 Genome
Project data, we found that the T allele frequency was
higher in the ccRCC patients compared with the healthy
subjects. Moreover, when correlating the different C1772T
genotypes with the HIF-1a protein nuclear expression, we
found the C/C genotype to be associated with a higher
nuclear protein expression (p = 0.021). Conversely, sam-
ples carrying the T/T genotype did not express HIF-1a in
the nucleus. Not surprisingly, heterozygous samples had
50 % presence and 50 % absence of the nuclear HIF-1a
protein expression. These data suggest that the C1772T
SNP may influence the HIF-1a nuclear expression or,
likely, the recruitment of transcriptional cofactors may be
enhanced or suppressed depending on the specific allele
through conformational changes caused by amino acid
substitution. Studies aiming at assessing the functional role
of this SNP on the protein nuclear localization are required
to exploit this intriguing association.
When assessing the genotype association with TSS,
quite surprisingly, we found that the T/T genotype overall
associated with a better TSS (Fig. 2b), suggesting that
carrying the T allele in homozygosis may determine an
advantage in terms of prognosis. The mechanisms behind
this phenomenon are not known. We are currently under-
taking studies to exploit this association.
Conclusions
In conclusion, our study provides insights about the
molecular alteration of VHL/HIF-1a axis in early-stage
ccRCC and show the potential role of HIF-1a C1772T SNP
in affecting HIF-1a protein nuclear expression. Additional
functional studies are, however, required to unmask the
mechanisms underlying such association.
Fig. 2 Kaplan–Meier curves of
samples carrying no and
biallelic alterations (a) and
carrying T1772T, C1772T, and
C1772C genotypes
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